Analyzing how individual children respond to radiation in cancer treatment
Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology
This study is testing how different children react to radiation during cancer treatment to help doctors give safer and more effective care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 3 Years to 18 Years |
| Sex | All |
| Sponsor | Neolys Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Caen and 1 other locations) |
| Trial ID | NCT06033183 on ClinicalTrials.gov |
What this trial studies
This study focuses on understanding the individual radiosensitivity of pediatric patients undergoing treatment for various types of cancer, including brain tumors and neuroblastoma. By analyzing blood samples from children and adolescents aged 3 to 18 who are receiving radiotherapy, the research aims to identify factors that influence how patients respond to radiation therapy. The goal is to improve treatment outcomes and minimize radiation toxicity by tailoring therapies based on individual sensitivity. This integrative molecular analysis could lead to more personalized cancer care for young patients.
Who should consider this trial
Good fit: Ideal candidates are children and adolescents aged 3 to 18 who are being treated for specific types of tumors with radiotherapy.
Not a fit: Patients who are receiving palliative radiotherapy or have contraindications to blood sampling or radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and safer radiation treatments for children with cancer.
How similar studies have performed: Other studies have shown promise in personalizing cancer treatment based on radiosensitivity, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes. * Children or adolescents \> 3 years old and \< 18 years old * Patient with an indication for radiotherapy as part of the primary tumor local control strategy * Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used * Patient affiliated with a social security scheme * Patient and/or parents or holders of parental authority having dated and signed an informed consent Exclusion criteria: * Patients with contraindications to blood sampling * Patients with contraindications to radiotherapy * Palliative radiotherapy * Patient with previous RT treatment in the same area (re-irradiation) * Patient with an indication of hypofractionated RT * Patient follow-up not possible * Persons deprived of liberty or under guardianship (including curatorship) Exclusion Criteria: \-
Where this trial is running
Caen and 1 other locations
- Centre François Baclesse — Caen, France (Recruiting)
- Centre Oscar Lambret — Lille, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Sandrine PEREIRA, PhD
- Email: spereira@neolys-diagnostics.fr
- Phone: 0643957510
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.